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ABSTRACT	  NK	  cells	  and	  T	  cells	  constitute	  a	  major	  part	  of	  the	  cell-­‐mediated	  immune	  system	  and	  play	   important	   roles	   in	   the	   host	   defense	   against	   viral	   infections.	   Most	   current	  knowledge	   of	   cell-­‐mediated	   immune	   responses	   to	   primary	   acute	   viral	   infections	  comes	  from	  murine	  models,	  while	  relatively	  less	  is	  known	  about	  human	  responses	  to,	  in	  particular,	  acute	  viral	  infections.	  In	  this	  thesis,	  the	  aim	  was	  to	  explore	  the	  early	  cell-­‐mediated	  immune	  responses	  to	  acute	  viral	   infections	  in	  humans.	  The	  live	  attenuated	  yellow	  fever	  virus	  vaccine	  (YFV	  17D)	  was	  used	  as	  a	  human	  in	  vivo	  model	  to	  study	  the	  dynamics	  and	  regulation	  of	  NK	  cell	  and	  T	  cell	   responses	   to	   the	   infection.	   In	  parallel,	  the	   NK	   cell	   and	   T	   cell	   responses	   to	   a	   natural	   acute	   infection	   caused	   by	   tick-­‐borne	  encephalitis	  virus	  (TBEV)	  were	  studied.	  	  Infection	  with	  YFV	  17D	  induced	  activation	  of	  NK	  cells	  and	  T	  cells.	  An	  early	  activation	  in	  NK	  cell	  function,	  around	  one	  week	  post-­‐vaccination,	  could	  be	  observed	  along	  with	  increased	  functions	  in	  response	  to	  target	  cells.	  A	  specific	  effector	  CD8	  T	  cell	  response	  occurred	  that	  reached	  a	  peak	  of	  activation	  around	  two	  weeks	  post-­‐vaccination,	  while	  CD4	  T	  cell	  activation	  peaked	  earlier,	  around	  day	  10,	  preceding	  that	  of	  CD8	  T	  cells.	  The	  functional	  profile	  of	  the	  YFV	  17D-­‐specific	  CD8	  T	  cell	  response	  changed	  in	  composition	  as	  it	  matured	  from	  an	  effector-­‐	  to	  a	  memory-­‐type	  response,	  and	  tended	  to	  become	  less	  polyfunctional	  during	  the	  course	  of	  this	  transition.	  In	  TBEV	  infected	  patients,	  NK	  cells	  were	  activated	  at	  the	  time	  of	  hospitalization.	  The	  activation	  subsequently	  decreased	  to	  healthy	  control	  levels.	  Simultaneous	  activation	  of	  CD8	  and	  CD4	  T	  cells	  occurred	  at	  one	  week	   following	   hospitalization	   and	   the	   TBEV-­‐specific	   CD8	   T	   cells	   showed	   a	   mono-­‐functional	   profile	   that	   persisted	   over	   time.	   Furthermore,	   TBEV-­‐specific	   CD8	   T	   cells	  showed	  a	  distinct	  transcriptional	  profile	  in	  the	  effector	  phase	  of	  the	  T	  cell	  response.	  	  Results	  presented	  in	  this	  thesis	  contribute	  to	  the	  understanding	  of	  the	  early	  T	  cell	  and	  NK	  cell	  responses	  in	  two	  human	  acute	  viral	  infections.	  In	  addition,	  they	  demonstrate	  that	  these	  two	  flaviviruses	  induce	  immune	  responses	  with	  different	  characteristics	  in	  infected	  humans.	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  1 
1 INTRODUCTION	  	  One	  of	  the	  first	  references	  to	  immunity	  in	  humans	  stems	  from	  the	  plague	  of	  Athens	  in	  430	  BC.	  The	  historian	  Thucydides	   (who	   survived	   the	  disease)	  noted	   that	  people	  who	  recovered	  from	  the	  plague	  could	  nurse	  the	  sick	  without	  contracting	  the	  illness	  a	  second	  time	   [1].	   The	   earliest	   forms	   of	   vaccination	   likely	   occurred	   in	   China	   during	   the	   10th	  century,	  where	  it	  was	  known	  that	  smallpox	  infection	  could	  be	  prevented	  by	  deliberate	  inoculation	  of	  the	  smallpox	  virus	  to	  uninfected	  individuals	  [2].	  The	  basis	  for	  this	  rather	  harmful	   vaccination	  was	   further	   improved	   in	   the	   18th	   century,	  when	  Edward	   Jenner	  noted	   that	   dairy	   workers	   never	   contracted	   smallpox	   and	   speculated	   that	   this	   was	  because	  they	  had	  already	  been	   infected	  with	  cowpox,	  a	   less	  virulent	  virus	   in	  humans.	  Jenner	  took	  pus	  from	  the	  hand	  of	  a	  milkmaid	  with	  cowpox	  and	  scratched	  it	  into	  the	  arm	  of	   an	   8-­‐year-­‐old	   boy.	   Six	   weeks	   later,	   Jenner	   inoculated	   the	   boy	   with	   smallpox	   and	  observed	   that	   he	   did	   not	   contract	   the	   disease	   [3].	   In	   the	   19th	   century,	   Louis	   Pasteur	  made	  observations	  of	  acquired	   immunity	  and	  created	  the	   first	  vaccines	  against	  rabies	  and	   anthrax.	   His	   discoveries	   supported	   the	   theory	   that	   some	   diseases	   are	   caused	   by	  microorganisms	   (the	   germ	   theory)	   [4],	   which	   was	   in	   direct	   opposition	   to	   the	  contemporary	   theories	   of	   diseases,	   in	  which	   “bad	   air”	  were	   thought	   to	   cause	   disease	  (the	  miasma	   theory)	   [5].	   It	  was	  not	  until	  1891	  Robert	  Koch	  established	   the	  causative	  relationship	  between	  microbes	   and	  disease.	   For	   this	   he	  was	   awarded	  with	   the	  Nobel	  Prize	   in	   physiology	   or	  medicine	   in	   1905.	   Yellow	   fever	  was	   the	   first	   identified	  human	  disease	  to	  be	  caused	  by	  a	  virus.	  In	  1901,	  Walter	  Reed	  verified	  the	  existing	  theory	  that	  yellow	  fever	  is	  transmitted	  by	  mosquitoes	  and	  not	  by	  human	  to	  human	  contact,	  thereby	  connecting	  arthropods	  to	  disease	  [6].	  
1.1 FLAVIVIRUSES	  	  The	  Flaviviridae	  family	  of	  viruses	  are	  divided	  into	  hepacivirus,	  flavivirus,	  pegivirus	  and	  pestivirus	  genera	  and	  they	  include	  many	  human	  pathogens.	  The	  family	  name	  originates	  from	  the	  yellow	  fever	  virus	  itself;	  flavus	  meaning	  yellow	  in	  latin.	  Flaviviridae	  viruses	  are	  enveloped	  and	  have	  a	  positive-­‐sense	  single	  stranded	  RNA	  genome,	  which	  upon	  entry	  is	  recognized	   as	  messenger	   RNA	   in	   the	   host	   cell.	   This	   allows	   the	   virus	   to	   replicate	   and	  produce	  a	  polyprotein	   that	   is	  processed	   into	   ten	  proteins.	  The	   flaviviruses	  have	   three	  structural	  proteins;	  capsid	  (C),	  precursor	  membrane	  (prM)	  and	  envelope	  glycoproteins	  (E)	   that	   constitute	   the	   core	   of	   the	   virion	   (Figure	  1A).	   There	   are	   seven	  non-­‐structural	  proteins:	   NS1,	   NS2A,	  NS2B,	  NS3,	   NS4A,	  NS4B,	   and	  NS5	   (Figure	   1B),	   that	   associate	   to	  form	  a	  replicase	  complex	  that	  catalyses	  RNA	  accumulation	  in	  association	  with	  modified	  cytoplasmic	  membranes	   [7].	  NS1	   is	   a	   protein	  unique	   to	   flaviviruses,	   and	   intracellular	  expression	  of	  NS1	  within	  the	  lumen	  of	  the	  ER	  is	  required	  for	  viral	  replication	  and	  viral	  RNA	   synthesis	   [8].	   NS1	   is	   synthesized	   as	   a	   monomer,	   after	   posttranslational	  modification	  in	  the	  lumen	  of	  the	  ER	  NS1	  dimerizes,	  and	  is	  secreted	  into	  the	  extracellular	  space	  as	  a	  hexameric	  lipoprotein	  particle	  [9].	  Dimeric	  NS1	  is	  expressed	  directly	  on	  the	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plasma	  membrane	  of	  infected	  cells	  [10].	  The	  two	  hydrophobic	  proteins	  NS2A	  and	  NS2B	  are	   encoded	   upstream	   of	   NS3	   in	   the	   polyprotein.	   One	   of	   these,	   NS2B,	   is	   the	   NS3	  protease	  cofactor	  whereas	  the	  other,	  NS2A,	  is	  an	  essential	  component	  of	  the	  replicase	  [11].	  NS3	   is	   a	  multifunctional	   enzyme	   that	   together	  with	   the	  NS2B	  cofactor	  mediates	  cleavage	  of	  the	  flavivirus	  C	  protein	  from	  its	  membrane	  anchor,	  and	  is	  therefore	  essential	  for	  maturation.	  NS4A	  and	  NS2B	  are	  cofactors	  that	  contribute	  to	  the	  structure	  of	  NS3	  anchoring	   the	   enzyme	   to	   the	  membrane,	   they	   are	   required	   for	  most	   NS3-­‐mediated	  processing	   events	   and	   can	   modulate	   NS3	   helicase	   activity.	   NS5	   protein	   has	   RNA-­‐dependent	   RNA	   polymerase	   (RdRp)	   and	   methyltransferase	   activities	   that	   are	  important	  for	  RNA	  synthesis	  and	  genome	  capping,	  respectively.	  NS2A,	  NS4A	  and	  NS4B	  proteins	  have	  so	  far	  undefined,	  but	  essential,	  roles	  in	  RNA	  accumulation	  [12].	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virions	  occurs	  in	  the	  ER,	  and	  the	  viral	  particles	  are	  transported	  to	  the	  Golgi	  apparatus	  [15,	  16].	  Formation	  of	  a	  deficient	   capsid	  and	  RNA	  particles	   is	  a	  hallmark	  of	   flavivirus	  infections.	  The	  virion	  particles	  are	  immature	  until	  the	  envelope	  protein	  is	  rearranged	  and	  prM	  are	  cleaved	  to	  M	  by	  furin	  (Figure	  1A)	  in	  the	  acidic	  environment	  in	  the	  Golgi	  apparatus	  [17,	  18].	  Immature	  particles	  are	  noninfectious	  [17]	  and	  whereas	  proteolytic	  cleavage	  of	  prM	  is	  a	  prerequisite	  for	  viral	  infectivity,	  studies	  have	  shown	  that	  complete	  cleavage	  is	  not	  necessary	  for	  infectivity	  [19].	  	  Diseases	  caused	  by	  flaviviruses	  are	  divided	  into	  hemorrhagic	  e.g.,	  yellow	  fever,	  dengue	  fever	  and	  West	  Nile	  fever	  and	  encephalitic	  e.g.,	  tick-­‐borne	  encephalitis	  (TBE),	  japanese	  encephalitis	   (JE).	   Flaviviruses	   are	   further	   divided	   into	   two	   clades:	   vector	   borne	   and	  viruses	  with	  unknown	  vectors	  [20].	  The	  vector	  borne	  clade	  can	  in	  turn	  be	  divided	  into	  a	  mosquito-­‐borne	   clade	   and	   a	   tick-­‐borne	   clade	   [21].	   The	   yellow	   fever	   virus	   (YFV)	   is	  transmitted	   to	  humans	  by	   the	  Aedes	  aegypti	  mosquito.	  The	  virus	  causes	  an	  estimated	  200,000	  illnesses	  and	  30,000	  deaths	  yearly,	  and	  90%	  of	  these	  infections	  occur	  in	  Africa.	  Yellow	  fever	  can	  be	  associated	  with	  acute	  immunopathology,	  including	  life-­‐threatening	  viral	   hemorrhagic	   fever	   [22,	   23].	   The	   vast	   majority	   of	   yellow	   fever	   cases	   are	  preventable,	   because	   of	   an	   effective	   vaccine	   that	   was	   developed	   in	   the	   1930s	   after	  successful	   attenuation	   of	   the	   YFV	   Asibi	   strain	   [24].	   The	   yellow	   fever	   vaccine	   has	   in	  recent	  years	  received	  renewed	  attention	  due	  to	  its	  high	  efficacy	  and	  safety,	  and	  since	  it	  provides	  a	  model	   for	  studies	  of	  human	  immune	  responses	  to	  a	  mild,	  but	  nevertheless	  replication-­‐competent,	  viral	  infection	  [25-­‐28].	  The	   first	   tick	   borne	   encephalitis-­‐like	   disease	   was	   described	   in	   Scandinavian	   church	  records	  from	  the	  18th	  century	  [29].	  Tick-­‐borne	  encephalitis	  virus	  (TBEV)	  is	  transmitted	  to	   humans	   by	   infected	   Ixodes	   tics,	   and	   it	   is	   estimated	   that	   one	   third	   of	   infected	  individuals	  develop	   clinical	   disease	   (Figure	  2).	  TBE	   is	   a	   biphasic	  disease	  where	  more	  than	  a	  third	  of	  the	  TBE	  patients	  will	  suffer	  from	  life-­‐long	  sequelae	  after	  the	  acute	  phase	  of	   the	   infection,	   including	   neuropsychiatric	   symptoms,	   severe	   headaches	   and	   a	  decreased	  quality	  of	   life	   [30].	  Numbers	  of	   reported	  cases	  have	   increased	  rapidly	  over	  the	   last	  decades	  in	  both	  Europe	  and	  Asia	  [31,	  32].	  Three	  subtypes	  of	  TBEV	  have	  been	  identified:	  European	  (TBEV-­‐Eu);	  Siberian	  (TBEV-­‐Sib);	  and	  Far	  Eastern	  (TBEV-­‐FE).	  The	  mortality	  rates	  differ	  between	  the	  strains,	  and	  infection	  with	  the	  far	  eastern	  strain	  have	  a	  mortality	  of	  5-­‐35	  %	  whereas	   the	  other	   two	  have	  reported	  mortalities	  of	  1-­‐3%	  [32].	  The	  pathogenesis	   of	  TBEV	   infection	   is	   far	   from	   fully	   understood.	  TBEV	  viral	   proteins	  and	   immune	  cell	   infiltrates	  have	  been	  detected	   in	  neuronal	   tissues	   from	  cases	  of	   fatal	  TBE,	  which	  indicates	  that	  the	  pathology	  could	  be	  mediated	  by	  direct	  viral	  effects	  as	  well	  as	  by	  immune-­‐mediated	  mechanisms	  [33,	  34].	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Figure	   2.	   Classical	   overview	  of	   the	   biphasic	   disease	   in	  TBEV	   infection.	   The	   first	   phase	   includes	   influenza-­‐like	  symptoms	  and	  occurs	  7-­‐14	  days	  after	  transmission.	  About	  65-­‐70%	  of	  infected	  individuals	  clear	  the	  virus,	  but	  for	  one	  third	   of	   the	   patients	   a	   second	   disease	   stage	   follows.	   The	   virus	   reaches	   the	   CNS	   and	   cause	   severe	   symptoms	   of	  meningitis	   or	   encephalitis	   e.g.,	   fever,	   severe	   headache,	   tremor,	   nystagmus,	   altered	   state	   of	   consciousness,	   cranial	  nerve	  paralysis	  and	  spinal	  nerve	  paralysis.	  There	  is	  no	  specific	  treatment	  for	  TBE,	  but	  the	  disease	  can	  be	  prevented	  by	  vaccination.	  There	  are	  Russian	  vaccines	  based	  on	  TBEV-­‐FE	  and	  in	  Europe	  two	  vaccines	  against	  TBE-­‐Eu	   strains	   are	   licensed	   (strain	   Neudoerfl,	   FSME-­‐IMMUN,	   Baxter	   Vaccines	   and	   Strain	  K23,	   Encepur,	   Novartis).	   The	   vaccines	   are	   based	   on	   formalin-­‐inactivated	   virus,	  however	   over	   the	   last	   years,	   an	   increased	   number	   of	   vaccine	   failures	   have	   been	  reported.	  There	  is	  a	  possibility	  that	  more	  vaccine	  failures	  remain	  unnoticed	  partly	  due	  to	  unusual	  antibody-­‐kinetics	  making	  it	  difficult	  to	  diagnose	  TBE	  in	  this	  group	  of	  patients	  [35].	  
1.2 NK	  CELLS	  Natural	   killer	   (NK)	   cells	  were	   first	   identified	   through	   their	   ability	   to	  mediate	   cellular	  cytotoxicity	   against	   tumor	   cells	   [36].	   The	   T	   cell	   receptor	   recognizes	   MHC	   class	   I,	   a	  necessity	   for	   the	  T	  cell	   to	  kill	   its	   target	  cells,	  and	  studies	  of	  NK	  cells	  were	   focused	  on	  finding	  a	  similar	  NK	  cell	  receptor,	  but	  no	  such	  receptor	  was	  found.	  It	  was	  observed	  that	  NK	  cells	  rather	  had	  the	  ability	  to	  kill	  cells	  lacking	  MHC	  class	  I,	  thus	  becoming	  activated	  by	  recognition	  of	   “missing	  self”	   (absence	  of	   self-­‐MHC	  class	   I	  molecules)	   [37].	  NK	  cells	  are	  identified	  as	  a	  component	  of	  the	  innate	  immune	  response	  against	  pathogens	  since	  they	  are	  activated	   in	  response	   to	   type	   I	   interferons	   (IFNs),	  do	  not	   rearrange	  genes	   to	  form	  receptors	  (like	  T	  and	  B	  cells	  do)	  and	  several	  other	  features	  [38].	  Although	  NK	  cells	  are	  considered	  as	  a	  part	  of	  the	  innate	  immune	  system,	  several	  studies	  in	  mice	  suggest	  they	  mediate	   recall	   responses	   to	   several	   pathogens	   and	   haptens	   [39-­‐41].	   Human	  NK	  cells	  are	  classically	  defined	  as	  CD3-­‐	  (T	  cell	  receptor	  negative),	  CD56+	  lymphocytes	  and	  represent	  about	  15%	  of	  peripheral	  blood	   lymphocytes.	  One	   important	   function	  of	  NK	  cells,	  in	  particular	  NK	  cells	  of	  a	  CD56dim	  phenotype,	  is	  to	  induce	  cell	  lysis	  in	  malignant	  or	  virally	   infected	  cells.	  This	  cytolysis	   is	  mediated	  by	  a	  number	  of	  mechanisms	  including	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(I)	   exocytosis	   of	   cytoplasmic	   granules	   containing	   perforin	   and	   granzymes,	   (II)	   fas-­‐ligand-­‐mediated	   induction	   of	   apoptosis,	   (III)	   antibody-­‐dependent	   cellular	   cytotoxicity	  (ADCC)	  through	  activation	  of	  CD16	  (FCγ-­‐receptor).	  CD56bright,	  as	  well	  as	  to	  some	  extent	  also	   CD56dim	   NK	   cells,	   also	   play	   an	   important	   immunomodulatory	   role,	   bridging	   the	  adaptive	   and	   innate	   immune	   responses	   by	   the	   production	   of	   soluble	   factors	   such	   as	  cyto-­‐	   or	   chemokines	   [42].	   NK	   cells	   recognize	   infected	   cells	   through	   an	   arsenal	   of	  different	  activating	  and	  inhibitory	  receptors,	  and	  the	  interactions	  among	  down-­‐stream	  signals	   are	   still	   not	   entirely	   understood.	   This	   thesis	   will	   focus	   primarily	   on	   a	   few	   of	  these	  receptors	  that	  are	  likely	  important	  in	  human	  viral	  infection.	  
1.2.1	  NK	  cell	  receptors	  	  
Killer	  Immunoglobulin-­‐like	  Receptors	  Humans	  and	  mice	  have	  two	  structurally	  distinct	  but	  functionally	  similar	  receptors	  that	  are	   important	   in	  regulating	  NK	  cell	   function.	   In	  humans,	   they	  are	  referred	   to	  as	  killer	  immunoglobulin	  like	  receptors	  (KIRs)	  that	  can	  activate	  signaling	  pathways	  that	  lead	  to	  inhibitory	   or	   activating	   outcomes	   in	   the	   NK	   cell	   (Figure	   3).	   This	   primarily	   occurs	  through	  interaction	  with	  MHC	  class	  I	  molecules	  [43].	  KIRs	  interact	  with	  classical	  (-­‐A,	  -­‐B	  and	  –C)	  and	  non-­‐classical	  (-­‐E	  and	  –G)	  HLA	  class	  I	  receptors.	  Activation	  or	  inhibition	  of	  NK	  cells	   is	  dependent	  on	  the	  strength	  of	  the	  binding	  between	  each	  KIR	  and	  its	   ligand,	  which	  is	  also	  partly	  dependent	  on	  the	  peptide	  presented	  by	  MHC	  class	  I.	  The	  proteins	  encoded	   by	   KIR	   genes	   have	   different	   immunoglobulin	   domains.	   KIRs	   that	   have	   two	  immunoglobulin	  domains	  are	  named	  KIR2D	  and	  KIRs	  with	   three	  domains	  are	  named	  KIR3D.	   Whether	   the	   protein	   becomes	   activating	   or	   inhibitory	   is	   determined	   by	   the	  presence	  or	  absence	  of	  specific	  signaling	  motifs	  in	  the	  cytoplastic	  domain	  of	  the	  cell.	  The	  receptor	   is	   inhibitory	   if	   the	  cytoplastic	   tail	   is	   long	  (KIR2DL,	  KIR3DL).	   If	   the	  protein	   is	  short,	  i.e.	  it	  lacks	  the	  inhibitory	  motifs,	  it	  has	  an	  activating	  function	  (KIR2DS,	  KIR3DS).	  KIR3DL1	   and	   KIR3DS1,	   binds	   to	   the	   serological	   motif	   w4	   that	   is	   carried	   by	   HLA-­‐B	  molecules	   [44]	   while	   KIR2DL1,	   KIR2DL2	   and	   KIR2DL3	   all	   bind	   to	   HLA-­‐C	   molecules.	  Furthermore,	  HLA-­‐C	  alleles	  can	  carry	  either	  an	  aspargine	  at	  position	  80	  and	  are	   then	  classified	   as	   group	   1	   (HLA-­‐C1),	   or	   a	   lysine	   and	   then	   belong	   to	   group	   2	   (HLA-­‐C2).	  KIR2DL2/3	   preferentially	   binds	   HLA-­‐C1	   and	   KIR2DL1	   preferentially	   binds	   HLA-­‐C2,	  with	  the	  binding	  affinity	  of	  the	  latter	  combination	  being	  stronger	  than	  the	  former	  (Table	  1).	  The	  KIR	  gene	  family	  is	  highly	  polymorphic,	  and	  this	  further	  complicates	  the	  general	  NK	   cell	   response.	   Two	   alleles	   for	   each	  KIR	   gene	   exist	   and	   two	  main	  haplotypes	   have	  been	   identified.	   Haplotype	   A	   have	   inhibitory	   KIRs	   exclusively	   (with	   the	   exception	   of	  KIR2DS4),	   and	   haplotype	   B	   have	   both	   inhibitory	   and	   activating	   KIR	   genes.	   Thus,	  possible	  haplotypes	  are	  A/A,	  A/B	  and	  B/B	  [45].	  Since	  genes	  encoding	  for	  KIR	  receptors	  display	  a	  great	  diversity	   in	  number	  and	  are	  expressed	   in	  a	  stochastic	  manner,	  unique	  subsets	  of	  NK	  cells	  with	  different	  activation	  thresholds	  are	  formed.	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Figure	   3.	   NK	   cell	   activation	   is	   regulated	   by	   the	   balance	   between	   activating	   and	  
inhibitory	  signals.	  Upon	  virus	  infection,	  MHC	  class	  I	  ligands	  for	  inhibitory	  receptors	  are	  often	  reduced	  or	   lost.	  The	  NK	  cell	  only	  receives	  activating	  signals	  and	  cytolytic	  effector	  molecules	  are	  released,	  which	  results	  in	  target-­‐cell	  killing.	  
Natural	  cytotoxicity	  receptors	  The	  majority	  of	  human	  NK	  cells	   express	   two	  activating	   receptors,	  NKp46	  and	  NKp30	  that	   belong	   to	   the	   family	   of	   natural	   cytotoxicity	   receptors	   (NCRs).	   There	   is	   a	   third	  member	  of	  the	  NCR	  family,	  NKp44,	  the	  expression	  of	  which	  can	  only	  be	  measured	  on	  NK	  cells	   that	  are	  activated	  by	   IL-­‐2	   [46].	  The	  NCR	  family	  belong	  to	   the	   Ig-­‐superfamily	  and	  have	   a	   transmembrane	   domain	   that	   associates	   with	   immunoreceptor	   tyrosine-­‐based	  activation	  motifs	  (ITAM)	  [47].	  The	  ligands	  for	  the	  NCRs	  are	  largely	  unknown,	  however,	  the	   interaction	   of	   several	   viral	   and	   tumor	   associated	  molecules	   have	   been	   observed	  [48].	   NKp46	   and	   NKp44	   have	   been	   claimed	   to	   interact	   with	   hemagglutinin	   (HA)	   on	  influenza	  virus	  and	  mediate	  cytolysis	  of	  influenza-­‐infected	  NK	  cells	  [49,	  50].	  	  

























	  	  	  
	  	  	  	  	  
	  	  NKG2D	  is	  another	  activating	  receptor,	  expressed	  on	  most	  NK	  cells,	  and	  is	  distinct	  from	  the	   other	   family	  members	   because	   it	   forms	   a	   homodimer	   in	   its	   active	   form.	   NKG2D	  recognizes	   a	   glycoprotein	   on	   human	   cytomegalovirus	   (CMV),	   and	   MHC	   class	   I	  polypeptide-­‐related	  sequence	  A	  and	  B	  (MICA	  and	  MICB)	  (Table	  1).	  NKG2D	  ligands	  are	  typically	   expressed	   on	   malignant	   or	   stressed	   cells,	   and	   multiple	   viral	   escape	  mechanisms	  are	  directed	  towards	  NKG2D.	  While	  the	  activating	  receptors	  of	  NKG2	  and	  KIRs	   bind	   ITAMs,	   the	   activating	  NKG2D	   binds	   a	   non-­‐ITAM	   sequence	   activating	   other	  pathways	  in	  the	  NK	  cell.	  	  
1.2.2	  NK	  cell	  differentiation	  and	  education	  	  NK	  cells	   are	  mainly	   identified	   through	   the	   surface	  marker	  CD56.	  They	   can	  be	   further	  subdivided	  into	  CD56bright	  and	  CD56dim	  NK	  cells	  depending	  on	  the	  intensity	  of	  CD56	  that	  is	   expressed	   on	   the	   cell	   surface.	   Most	   CD56bright	   NK	   cells	   lack	   CD16,	   express	   the	  inhibitory	  NKG2A	  receptor,	   and	  have	   low	  expression	  of	  KIRs	  and	  cytotoxic	  molecules	  such	  as	  perforin	  and	  granzymes,	  and	  are	  considered	  as	  a	  more	  immature	  set	  of	  NK	  cells.	  In	  contrast,	  most	  CD56dim	  NK	  cells	  express	  CD16,	  have	  a	  variegated	  expression	  of	  KIRs,	  lower	   expression	   of	   NKG2A	   and	   contain	   intracellular	   granules	   with	   perforin	   and	  granzymes	   [36]	   (Figure	   4).	   The	   function	   of	   NK	   cells	   is	   dependent	   on	   the	   stage	   of	  differentiation.	   Human	   NK	   cells	   continuously	   differentiate	   and	   this	   process	   is	  associated	   with	   functional	   changes	   [53-­‐55].	   CD56dim	   NK	   differentiation	   can	   be	  determined	  with	  the	  expression	  of	  CD57	  together	  with	  the	  expression	  of	  NKG2A,	  where	  CD57-­‐NKG2A+	   cells	   lacking	   KIRs	   represent	   the	   least	   differentiated	   subset,	   and	   the	  CD57+NKG2A-­‐	   subset	   expressing	   multiple	   KIRs	   represents	   the	   most	   differentiated	  subset	   [53]	   (Figure	   4).	   The	   late	   differentiated	   CD57+	  NK	   subsets	   are	   associated	  with	  
Receptor Function Ligand 
CD16 activating IgG 
NKp30 activating Unknown 
NKp44 activating HA 
NKp46 activating HA 
NKG2A inhibitory HLA-E 
NKG2C activating HLA-E 
NKG2D activating MICA/MICB, ULBP1-4 
KIR2DL1 inhibitory HLA-C2 
KIR2DS1 activating HLA-C2 
KIR2DL2 inhibitory HLA-C1 
KIR2DS2 activating HLA-C1 
KIR2DS4 activating HLA-A11, C1, C2 
KIR2DL3 inhibitory HLA-C1 
KIR3DL1 inhibitory HLA-B 
KIR3DS1 activating HLA-B 
Table	  1.	  Simplified	  overview	  of	  NK	  cell-­‐receptors,	  functions	  and	  ligands. 
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phenotypic	   and	   functional	   changes,	   such	   as	   a	   decline	   in	   proliferative	   capacity	   and	  responsiveness	   to	   cytokines	   together	   with	   increased	   ability	   to	   perform	   cytotoxic	  responses	  [54,	  55].	  	  
	  
Figure	  4.	   Schematic	   overview	  of	   CD56dim	  NK	   cell	   differentiation.	   The	   least	   differentiated	   CD56dim	  NK	   cells	   are	  CD57-­‐	  ,	  have	  low	  numbers	  of	  KIRs,	  are	  more	  prone	  to	  cytokine	  stimulation	  and	  have	  a	  large	  proliferative	  capacity.	  The	  late	  differentiated	  CD57+	  subsets	  are	  less	  responsive	  to	  cytokine	  stimulation,	  exhibit	  cytotoxic	  potential,	  and	  have	  a	  higher	  number	  of	  KIRs,	  thus	  they	  are	  more	  responsive	  to	  target	  cell	  killing.	  	  	  In	  order	  not	  to	  kill	  normal	  host-­‐cells,	  most	  NK	  cells	  are	  equipped	  with	  at	  least	  one	  self-­‐MHC-­‐class	   I	   receptor	   to	   maintain	   self-­‐tolerance.	   NK	   cells	   that	   express	   an	   inhibitory	  receptor	   (including	   inhibitory	   KIRs	   and	   NKG2A)	   for	   a	   self-­‐HLA	   class	   I	   molecule	   are	  educated,	   and	   respond	  well	   to	   stimulation	  with	  HLA	  class	   I-­‐negative	   target	   cells	   [56].	  NK	  cells	  that	  lack	  expression	  of	  inhibitory	  receptors	  for	  self-­‐HLA	  class	  I	  are	  considered	  “non-­‐educated”	  and	  are	  hypo-­‐responsive	  to	  stimulation	  with	  HLA	  class	  I-­‐negative	  target	  cells	  [56,	  57].	  This	  suggests	  that	  non-­‐educated	  NK	  cells	  may	  be	  particularly	  important	  in	  infections	  where	  HLA	  class	  I	   is	  not	  down-­‐regulated	  by	  the	  virus,	  and	  where	  cytokines	  produced	  by	  other	   immune	  cells	  drive	   the	  NK	  cell	  response.	  Conversely,	  educated	  NK	  cells	  may	  be	  more	  important	  in	  the	  response	  against	  virus	  infected	  cells	  that	  have	  down	  regulated	  HLA	  class	  I	  from	  the	  cell	  surface.	  	  	  
1.2.3	  NK	  cells	  in	  viral	  infections	  Functional	   NK	   cells	   are	   crucial	   in	   the	   control	   of	   many	   viral	   infections.	   NK	   cell	  deficiencies	   in	   humans	   result	   in	   severe	   viral	   infections	   in	   childhood	   and	   adolescence	  [58].	   In	   particular,	   it	   results	   in	   increased	   susceptibility	   to	   viral	   infections	   caused	   by	  herpes	   simplex	   virus	   (HSV),	   varicella	   zoster	   virus,	   cytomegalovirus	   and	   human	  papilloma	  virus	  [59-­‐61].	  NK	  cells	  are	  reported	  to	  control	  viral	  replication	  through	  killing	  of	   infected	  cells,	  and	   they	  also	  play	  an	   immune	  regulatory	  role	   in	   the	  development	  of	  adaptive	  immunity	  [62,	  63].	  Furthermore,	  NK	  cells	  can	  modulate	  the	  adaptive	  immunity	  directly	  through	  interacting	  with	  dendritic	  cells	  [62].	  NK	  cell-­‐responses	  have	  been	  studied	  both	   in	   the	  context	  of	   several	   chronic	  and	  some	  acute	   human	   viral	   infections,	   e.g.	   human	   immunodeficiency	   virus	   (HIV)	   [64],	  cytomegalovirus	   (CMV)	   [65,	   66],	   hepatitis	  B	   virus	   (HBV),	   hepatitis	  C	   virus	   (HCV)	   and	  hepatitis	  D	  virus	  (HDV)	  [67],	  hantavirus	  [68],	  as	  well	  as	  chikungunya	  virus	  [69].	  In	  some	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of	  these	  infections,	  it	  has	  been	  suggested	  that	  activated	  NK	  cells	  may	  be	  involved	  in	  the	  pathogenesis	  of	   the	   infection	  where	   the	  NK	  cells	  participate	  either	  by	  direct	  killing	  of	  infected	  cells,	  or	  by	  indirect	  killing	  through	  cyto-­‐	  or	  chemokines,	  or	  by	  the	  recruitment	  of	  inflammatory	  cells	  into	  the	  tissues	  [70,	  71].	  Accumulation	  of	  NK	  cells	  expressing	  the	  activating	   NKG2C	   receptor	   are	   reported	   in	   some	   human	   infections	   i.e.	   with	   CMV,	  hantavirus,	   chikungunya	   virus	   [68,	   69,	   72]	   and	   the	   expansion	   of	   this	   subset	   is	   even	  greater	   in	   CMV	   positive	   individuals	   [66,	   68,	   73].	   However,	   the	   expansion	   of	   NKG2C	  positive	  NK	  cells	  is	  not	  reported	  in	  all	  viral	  infections,	  as	  Epstein	  Barr	  virus	  (EBV)	  [74]	  and	   herpes	   simplex	   virus	   2	   (HSV-­‐2)	   [75]	   where	   infection	   do	   not	   cause	   specific	  expansion	  of	  NKG2C	  NK	  subsets.	  	  NK	   cells	   have	   also	   been	   studied	   to	   some	   extent	   in	   a	   number	   of	   human	   flavivirus	  infections	  including	  dengue	  fever	  [76,	  77],	  West	  Nile	  fever	  [78,	  79]	  as	  well	  as	  after	  live	  attenuated	  YFV	   vaccination	  with	  YFV	  17D	   [80,	   81].	   In	   these	   infections,	  NK	   cells	   have	  been	  suggested	  to	  affect	  disease	  severity	  and	  outcome	  as	  well	  as	  to	  contribute	  to	  viral	  control,	  even	  though	  the	  underlying	  mechanisms	  remain	  unknown.	  For	  example,	  in	  the	  case	  of	  dengue	  virus	  (DENV)	  infection,	  a	  higher	  absolute	  number	  of	  NK	  cells	  count	  was	  reported	   in	   patients	  with	   a	  mild	   infection	   as	   compared	   to	   patients	  with	  more	   severe	  form	  of	  dengue	  hemorrhagic	  fever	  (DHF)	  [82].	  The	  NK	  cell	  contribution	  in	  dengue	  fever	  is,	  however,	  not	  straightforward,	  since	  a	  higher	  percentage	  of	  activated	  NK	  cells	  early	  on	  during	   the	   infection	   in	   children	   developing	   severe	   DHF	   have	   been	   observed	   [83].	  Cytotoxic	   activity	   in	   NK	   cells	   have	   also	   been	   shown	   to	   be	   increased	   in	   early	   disease	  stages	  of	  DENV	  infection,	  and	  greater	  cytotoxicity	  has	  been	  reported	  in	  the	  more	  severe	  forms	   of	   the	   disease	   [84].	   In	   experimental	   systems,	   increased	   NK	   cell	   diversity	   was	  reported	  after	  exposure	  of	  human	  NK	  cells	  to	  West	  Nile	  virus	  (WNV)	  infected	  peripheral	  blood	  mononuclear	  cells	  (PBMC)	  [78]	  and	  primary	  activated	  human	  NK	  cells	  inhibited	  WNV	  infection	  of	  Vero	  cells	  in	  vitro	  [79].	  NK	  cell	  responses	  are	  not	  well	  studied	  in	  the	  context	  of	  TBEV-­‐infection.	  One	  study	  reports	  a	  decrease	  of	  the	  activation	  marker	  CD69	  upon	  in	  vitro	  infection	  of	  PBMC	  with	  TBEV	  [85].	  Patients	  with	  severe	  TBE	  (meningitis	  or	  encephalitis)	  have	  been	  reported	  to	  have	  higher	  percentages	  of	  NK	  cells	   in	  peripheral	  blood	   than	   in	   the	   cerebrospinal	   fluid	   (CSF)	   [86].	  NK	   cells	   have	   also	  been	   reported	   to	  decrease	  one	  week	  post	  vaccination	  and	  then	  return	  to	  normal	  healthy	  control	  levels	  by	  the	   end	   of	   the	   acute	   period	   of	   neuroinfection	   (day	   25-­‐30)	   in	   patients	   febrile	   TBEV-­‐infection	  [87].	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1.3 T	  CELLS	  T	   cells	   constitute	   one	  major	   part	   of	   the	   adaptive	   immune	   system.	   T	   cell	   responses	  establish	  an	  immunological	  memory	  to	  a	  pathogen	  after	  it	  has	  been	  cleared,	  and	  this	  leads	  to	  improved	  responses	  and	  often	  protection	  to	  subsequent	  encounters	  with	  that	  specific	  pathogen.	  T	  cells	  can	  be	  separated	  from	  other	  immune	  cells	  by	  the	  presence	  of	  the	  T	   cell	   receptor	   (TCR)	   expressed	  on	   the	   cell	   surface.	  The	   vast	  majority	   of	  T	   cells	  express	   alpha-­‐beta	  TCRs	   (αβ	  T	   cells),	   but	   some	  T	   cells	   in	   epithelial	   tissues	   (like	   the	  gut)	   express	   gamma-­‐delta	   TCRs	   (γδ	   T	   cells),	   which	   recognize	   non-­‐protein	   antigens.	  The	   TCR	   displays	   exquisite	   antigen	   specificity	   because	   of	   V(D)J	   recombination	   that	  generates	   the	  highly	  diverse	  repertoire	  of	  TCRs.	  CD4	  and	  CD8	  are	  surface	  molecules	  that	  act	  as	  co-­‐receptors	  to	  the	  TCR	  and	  they	  are	  expressed	  on	  different	  T	  cell	  subsets.	  CD4	  has	  a	  domain	  that	  interacts	  with	  MHC	  class	  II	  molecules	  and	  therefore,	  T	  cells	  that	  have	  CD4	  on	  their	  surface	  are	  MHC	  class	  II	  restricted.	  CD8	  is	  expressed	  on	  cytotoxic	  T	  cells	   and	   interact	   with	   MHC	   class	   I	   molecules,	   thus	   CD8	   T	   cells	   are	   MHC	   class	   I	  restricted.	  	  MHC	   class	   II	   molecules	   are	   expressed	   predominatly	   by	   “professional”	   antigen	  presenting	   cells	   (APCs),	   for	   instance	   macrophages	   or	   DCs.	   These	   cells	   take	   up	  microbes	  through	  phagocytosis,	  degrade	  them,	  and	  load	  MHC	  class	  II	  molecules	  with	  peptides.	   MHC	   class	   II	   presented	   antigenic	   peptides	   thus	   mostly	   originates	   from	  extracellular	  material.	  The	  peptides	  (antigens)	  presented	  by	  MHC	  class	  II	   to	  the	  TCR	  are	  normally	  15-­‐20	  amino	  acids	  long	  and	  the	  CD4	  T	  cells	  responding	  to	  antigens	  have	  critical	   functions	   in	   activating	   and	   regulating	   immune	   responses	   via	   the	   production	  and	   release	  of	  various	   cytokines.	  Thus	   they	  bridge	   innate	  and	  adaptive	   immunity	   in	  infection	   and	   they	   are	   traditionally	   referred	   to	   as	  T	  helper	   cells.	   CD4	  T	   cells	   can	  be	  divided	  into	  distinct	  subsets	  depending	  on	  their	  cytokine	  profile.	  In	  a	  simplified	  view,	  Th1	  subsets	  activate	  cellular	  immune	  responses	  via	  the	  production	  of	  IFN-­‐γ,	  TNF	  and	  IL-­‐2,	   and	   Th2	   subsets	   mainly	   produce	   cytokines	   supporting	   B	   cell	   activation	   [88].	  Regulatory	  T	  cell	  subsets	  (Treg)	  can	  be	  distinguished	  from	  other	  CD4	  T	  cell	  subsets	  by	  expression	   of	   the	   transcription	   factor	   FoxP3.	   Their	   main	   function	   is	   to	   regulate	  immune	   responses	   and	   prevent	   autoimmunity.	   They	   suppress	   cytotoxic	   T	   cell	  responses	   after	   successful	   clearance	   of	   pathogen,	   thereby	   controlling	   the	   cytotoxic	  response	  to	  infection	  to	  avoid	  immunopathology	  [89,	  90].	  	  	  MHC	  class	  I	  molecules	  are	  expressed	  on	  nearly	  all	  nucleated	  cells	  in	  the	  human	  body	  and	  are	  normally	  loaded	  with	  endogenous	  peptides,	  i.e.	  peptides	  from	  within	  the	  cell.	  These	  peptides	  are	  usually	  8-­‐10	  amino	  acids	  long.	  Similar	  to	  NK	  cells,	  the	  function	  of	  CD8	  T	  cells	   is	  to	  kill	   infected	  cells	  through	  the	  release	  of	  perforin	  and	  granzymes,	  as	  well	   as	   releasing	   cytokines	   such	   as	   IFN-­‐γ,	   TNF	   and	   IL-­‐2	   and	   recruit	   NK	   cells,	  macrophages	   and	   B	   cells	   to	   the	   cite	   of	   infection.	   T	   cells	   can	   also	   induce	   apoptosis	  though	  death	  receptors	  such	  as	  TRAIL	  and	  FASL	  [91].	  Since	  viruses	  utilize	  the	  host	  cell	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machinery,	  viral	  products	  are	  mainly	  presented	  by	  MHC	  class	  I	  molecules	  to	  the	  CD8	  T	  cells.	  
1.3.1	  T	  cell	  development	  and	  differentiation	  	  T	  cells	  mature	   in	   the	   thymus	  where	   they	  are	  exposed	   to	  endogeneous	   “self”	  peptides	  and	  undergo	  a	  process	  of	  positive	  and	  negative	   selection.	  Only	  T	   cells	   that	  bind	  MHC	  class	  I	  or	  MHC	  class	  II	  molecules	  with	  a	  suitable	  strength	  (not	  too	  strong	  or	  too	  weak)	  will	  survive	  the	  process.	  The	  earliest	  T	  cells	  are	  all	  negative	  for	  CD4	  and	  CD8,	  but	  as	  they	  progress	   through	   development,	   they	   become	   double	   positive	   (CD4+CD8+).	   The	  CD4+CD8+	   T	   cells	   that	   interact	   with	   MHC	   class	   II	   will	   down	   regulate	   CD8	   from	   the	  surface	  and	  become	  single	  positive	  CD4	  T	  cells,	  and	  CD8	  will	  remain	  on	  the	  surface	  of	  the	  cells	  that	   interact	  with	  MHC	  class	  I.	  T	  cells	   leave	  the	  thymus	  as	  immature,	  naive	  T	  cells.	  The	  engagement	  and	  binding	  of	   the	  CD3/TCR	  complex	  to	  a	  peptide-­‐loaded	  MHC	  molecule	   (pMHC)	   will	   activate	   a	   naive	   T	   cell,	   but	   efficient	   activation	   requires	   co-­‐stimulation	  through	  dedicated	  co-­‐stimulatory	  receptors.	  If	  the	  T	  cell	  do	  not	  receive	  the	  second	  co-­‐stimulatory	  signal,	  it	  will	  undergo	  apoptosis	  [92].	  This	  activation,	  or	  priming,	  by	   an	   APC,	  will	   allow	   the	   T	   cell	   to	  mature,	   divide	   and	   differentiate	   into	   effector	   and	  memory	  cells.	  A	   typical	  co-­‐receptor,	   found	  on	  the	  surface	  of	   the	  T	  cell	   is	  CD28,	  which	  binds	   to	   CD80	   or	   CD86	   on	   the	   APC	   to	   initiate	   activation	   [93].	   When	   a	   CD8	   T	   cell	  becomes	  activated,	   it	  proliferates	  and	  this	  clonal	  expansion	   is	  supported	  by	   the	  T	  cell	  growth	  factor	  IL-­‐2.	  	  The	  T	  cell	  differentiates	  into	  subsets	  of	  effector	  cells,	  many	  of	  which	  enter	  the	  blood	  and	  migrate	  to	  sites	  of	  infection.	  Following	  clearance	  of	  a	  pathogen,	  the	  effector	   T	   cell	   population	   contracts	   and	   the	  majority	   of	   the	   pathogen-­‐specific	   T	   cells	  enter	  apoptosis.	  A	  small	  pool	  of	  pathogen	  specific	  T	  cells	  (5-­‐10%)	  survives	  as	  memory	  cells	  [94].	  The	  CD8	  T	  cells	  destined	  to	  survive	  are	  sometimes	  referred	  to	  as	  long-­‐lived	  memory	  precursor	  effector	  cells	  (MPECs)	  and	  tend	  to	  have	  a	  higher	  expression	  of	   the	  IL-­‐7R	  (CD127)	  than	  the	  short-­‐lived	  effector	  cells	  (SLECs)	  that	  do	  not	  survive	  [95].	  Not	  all	  IL-­‐7Rhigh	  effector	  CD8	  T	  cells	  become	  memory	  cells,	  so	  IL-­‐7R	  alone	  does	  not	  indicate	  the	   fate	   of	   the	   CD8	   T	   cell.	   The	   pool	   of	   memory	   cells	   is	   maintained	   in	   a	   cytokine-­‐	  dependent	  manner	  mainly	  through	  the	  actions	  of	  IL-­‐7	  and	  IL-­‐15	  to	  promote	  memory	  T	  cell	  survival,	  independently	  of	  specific	  antigen	  [96].	  Upon	  re-­‐exposure	  to	  the	  pathogen,	  the	  memory	  cells	  quickly	  expand	  to	  large	  numbers	  of	  effector	  T	  cells	  (Figure	  5).	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Figure	  5.	  Primary	  anti-­‐viral	  T	  cell	  responses	  go	  through	  a	  phase	  of	  rapid	  proliferation	  and	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In	   the	   last	   decade,	   much	   attention	   has	   been	   directed	   towards	   the	   identification	   of	  transcription	  factors	  that	  regulate	  T	  cell	  differentiation	  of	  effector	  and	  memory	  T	  cells.	  Many	   transcription	   factors	   have	   been	   identified	   that	   have	   potentially	   important	  effects	   on	   gene	   expression	   in	   effector	   and	   memory	   T	   cells.	   They	   are	   believed	   to	  operate	   in	   pairs	   in	   opposing	   ways	   to	   facilitate	   effector	   versus	   memory	   T	   cell	   fates	  [100].	  The	  T-­‐box	   transcription	   factors	  T-­‐bet	   and	  Eomesodermin	   (Eomes)	  have	  been	  shown	  to	  play	  important	  roles	  in	  determining	  the	  fate	  of	  CD8	  T	  cells	  during	  infection	  [95,	   101,	   102].	   High	   expression	   of	   T-­‐bet	   promotes	   differentiation	   towards	   a	   more	  terminally	  differentiated	  profile	  [95,	  103].	  Eomes	  is	  homologous	  to	  T-­‐bet	  in	  the	  DNA-­‐binding	  domain,	  but	  it	  promotes	  the	  development	  of	  memory	  CD8	  T	  cells	  rather	  than	  effector	   T	   cells	   [101,	   104]	   (Figure	   6).	   Genetic	   deletion	   of	   T-­‐bet	   abrogates	   the	  formation	   of	   effector	   CD8	   T	   cells,	   whereas	   the	   IL7R+	   central	   memory	   subsets	   are	  sustained	   [95].	  Additionally,	   IL-­‐2	  expression	  has	  been	  positively	   correlated	  with	   the	  expression	  of	  T-­‐bet,	  which	  indicate	  a	  link	  between	  inflammation	  and	  accumulation	  of	  terminal	   effector	   cells	   [105].	   Deletion	   of	   Eomes	   results	   in	   deficient	  memory	   T	   cells	  while	   the	   effector	   T	   cells	   are	   sustained	   [106].	   Both	   T-­‐bet	   and	   Eomes	   can	   be,	   and	  probably	  are,	  expressed	  at	   the	  same	  time	   in	  a	  cell	  but	   the	  gradient	  of	   these	  two	  will	  determine	  the	  fate	  of	  the	  T	  cell	  [95].	  	  	   
	  
Figure	  6.	  Schematic	  presentation	  of	  T	  cell	  subsets.	  The	  early	  CCR7+	  T	  cells	  are	  positive	  for	  the	  co-­‐receptor	  CD27,	  and	  in	  most	  cases	  positive	  for	  the	  IL-­‐7Rα	  (CD127),	  have	  low	  content	  of	  perforin,	  granzymes,	  and	  T-­‐bet.	  The	  mature	  CCR7-­‐	  subsets	  leave	  the	  lymph	  nodes	  and	  enter	  the	  periphery.	  They	  have	  a	  higher	  expression	  of	  perforin,	  granzyme	  and	  T-­‐bet,	  shorter	  telomere	  lengths	  and	  are	  in	  most	  cases	  negative	  for	  the	  IL-­‐7Rα.	  	  
1.3.2 T	  cell	  immunity	  against	  viruses	  The	   ultimate	   immune	   response	   to	   a	   viral	   infection	   is	   initiated	   by	   a	   balanced	   innate	  response	   that	   limits	   viral	   replication,	   followed	  by	   a	   highly	   specific	   adaptive	   response	  that	  contains	  and	  eliminates	  the	  invading	  pathogen.	  In	  reality,	  however,	  many	  immune	  responses	   are	   less	   successful	   and	   persistent	   damage	   to	   the	   host	   as	   well	   as	   chronic	  infection	  may	  be	  the	  outcome.	  	  






















CD4	  T	  cells	  play	  an	  important	  role	  in	  the	  protective	  immunity	  against	  viruses,	  primed	  by	  infection	  or	  by	  vaccination.	  CD4	  T	  cells	  can:	  (I)	  promote	  contact	  of	  CD8	  T	  cells	  with	  DCs	  in	  secondary	  lymphoid	  tissue	  [107,	  108];	  (II)	  recruit	  lymphoid	  cells	  into	  draining	  lymph	  nodes	   [109];	   (III)	   recruit	   innate	   or	   antigen-­‐specific	   effectors	   to	   the	   site	   of	   viral	  replication	   [110,	   111].	   Furthermore,	   non-­‐traditional	   cytotoxic	  MHC	   class	   II	   restricted	  CD4	  T	  cells	  can	  occur	  and	  have	  been	  suggested	  to	  be	  important	  in	  viral	  control	  [112].	  Due	   to	  difficulties	   in	   identifying	   the	  acute	  phase	  of	  viral	   infection	   in	  humans,	  most	  of	  current	  knowledge	  of	  antigen-­‐specific	  T	  cell	  responses	  to	  acute	  primary	  viral	  infections	  comes	   from	   murine	   models,	   where	   responses	   to	   viruses	   such	   as	   lymphocytic	  choriomeningitis	  virus	  (LCMV)	  or	  vaccinia	  virus	  have	  been	  studied	  [113,	  114].	  	  Studies	  of	   human	  T	   cell	   responses	   to	   viral	   infections	   have	   to	   a	   large	   extent	   been	   focused	   on	  pathogens	  causing	  chronic	  infections	  with	  wide	  implications	  for	  human	  health	  such	  as	  HIV-­‐1,	  EBV,	  HCV	  and	  CMV	  [115-­‐119].	  Such	  responses	  can	  be	  very	  robust,	  as	  exemplified	  by	   the	  massive	   clonal	   expansion	   of	   antigen-­‐specific	   CD8	  T	   cells	   [117,	   119].	   Based	   on	  these	  studies,	   it	  has	  also	  become	  clear	  that	   the	  resulting	  populations	  of	  human	  CD8	  T	  cells	  display	  striking	  phenotypic	  differences,	  as	  determined	  by	  the	  expression	  profiles	  of	  surface	  markers	   [97,	   98,	   115].	   The	   phenotype	   required	   to	   control	   the	   infection	  most	  likely	   differs	   depending	   on	   the	   antigen.	   Terminally	   differentiated	   CD8	   TEMRA	   cells	  dominate	   the	   response	   in	   persistent	   CMV	   infection	   [115,	   119],	  whereas	   intermediate	  TEM	  cells	  dominate	   the	  response	   in	  HIV-­‐infected	   individuals	   [115].	   It	  has	   further	  been	  reported	  that	  TEMRA	  cells	  may	  be	   involved	   in	  protective	   immunity	  against	  HIV-­‐1,	  since	  HIV-­‐specific	  T	  cells	  with	  this	  phenotype	  were	  associated	  with	  viral	  control	  [120,	  121].	  	  Furthermore,	  during	  chronic	  infections	  with	  viruses	  such	  as	  HIV-­‐1	  and	  HCV	  in	  humans,	  the	   persistent	   exposure	   to	   viral	   antigens	   alters	   the	   function	   and	   gene	   expression	   of	  virus-­‐specific	  CD8	  T	  cells.	  Such	  changes	  are	  referred	  to	  as	  T	  cell	  ‘exhaustion’	  because	  the	  antigen-­‐specific	  T	  cells	  display	  a	  hierarchical	  loss	  of	  IL-­‐2,	  TNF	  and	  IFN-­‐γ,	  have	  impaired	  proliferation	   and,	   to	   some	   degree,	   decreased	   cytotoxic	   activity	   [122,	   123].	   The	  maintenance	  of	  antigen-­‐specific	  T	  cells	  during	  chronic	  viral	  infection	  seems	  to	  be	  more	  dependent	   on	   the	   presence	   of	   the	   antigen	   and	   less	   dependent	   on	   IL-­‐7	   and	   IL-­‐15,	   in	  contrast	   to	   the	   maintenance	   of	   the	   functional	   memory	   T	   cells	   that	   form	   after	   acute	  infection	  or	  in	  response	  to	  most	  vaccines	  [124].	  Moreover,	  the	  cooperative	  expression	  of	  T-­‐bet	  and	  Eomes	  in	  chronic	  infection	  is	  believed	  to	  be	  critical	  to	  sustain	  viral	  control	  since	  deletion	  of	  either	  one	  of	   them	  resulted	   in	   failure	   to	  control	   infection	   [125].	  The	  expression	   patterns	   of	   T-­‐bet	   and	   Eomes	   in	   CD8	   T	   cells	   are	   not	   yet	   completely	  understood,	   and	   the	   analysis	   of	   these	   transcription	   factors	   during	   CD8	   T	   cell	  differentiation	   may	   bring	   a	   novel	   molecular	   perspective	   to	   the	   phenotypic	  characterization	  of	  CD8	  T	  cells	  and	  a	  deeper	  understanding	  of	  CD8	  T	  cell	  differentiation	  during	  both	  acute	  and	  chronic	  viral	  infections.	  In	   flavivirus	   infections,	   it	   has	   been	   discussed	   if	   the	   role	   of	   T	   cells	   is	   protective	   or	  pathogenic.	   For	   instance,	   CD8	   T	   cells	   use	   a	   perforin-­‐dependent	   mechanism	   to	   clear	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WNV	  from	  infected	  neurons,	  despite	  the	  risk	  of	  immunopathogenesis	  [126].	  T	  cells	  are	  believed	  to	  be	  protective	  in	  DENV	  infection,	  with	  higher	  frequencies	  of	  DENV-­‐specific	  T	  cells	   observed	   in	   school	   children	   who	   subsequently	   developed	   subclinical	   infection,	  compared	  with	  those	  who	  developed	  symptomatic	  secondary	  infection	  [127].	  	  Previous	  reports	   have	   shown	   that	   CD8	   T	   cells	   play	   a	   key	   role	   in	   the	   pathogenesis	   of	   TBEV-­‐infection.	  Cytotoxic	  T	   cell	   infiltrates	  have	  been	   linked	   to	   cell-­‐death	   in	   infected	  human	  neuronal	  tissue	  [34]	  and	  mice	  that	  are	  deficient	  in	  CD8	  T	  cells	  have	  a	  prolonged	  survival	  as	   compared	   to	   immuno-­‐competent	  mice,	   or	  mice	  with	   adoptively	   transferred	  CD8	  T	  cells	  [128].	  Together,	  these	  data	  suggest	  that	  there	  may	  be	  a	  dual	  role	  of	  CD8	  T	  cells,	  as	  they	   can	   be	   important	   in	   clearing	   viral	   infection	   but	   also	  mediate	   immunopathology	  within	  the	  CNS.	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2 METHODS	  The	   work	   in	   this	   thesis	   mainly	   relies	   on	   the	   analysis	   of	   advanced	   multicolor	   flow	  cytomery.	  The	  first	  flow	  cytometer	  was	  developed	  in	  the	  1950s	  and	  have	  over	  the	  past	  decades	  become	  an	  extensively	  used	  technique	  to	  study	  immune	  cells	  [129].	  An	  arsenal	  of	   receptors,	   chemokines,	   transcription	   factors	   and	   other	   molecules	   are	   used	   to	  determine	   the	   character	   of	   the	   cell.	   In	   this	   thesis,	   several	   multicolor	  immunofluorescence	  panels	  have	  been	  optimized	  to	  study	  the	  phenotype	  and	  character	  of	  NK	  cells	  and	  T	  cells	  in	  flavivirus	  infections.	  	  In	  order	  to	  identify	  virus-­‐specific	  T	  cells	  with	  flow	  cytometry	  (as	  in	  Paper	  III	  and	  IV),	  T	  cell	  epitopes	   in	   the	  virus	  have	   to	  be	   identified	   if	   they	  are	  not	  already	  known.	  Epitope	  identification	  requires	  a	  systematic	  screening	  of	  the	  antigen,	  which	  can	  be	  difficult	  when	  the	  antigen	  has	  multiple	  conformations	  or	  binding	  domains.	  Peptide	  libraries	  are	  used	  to	  display	  multiple,	  linear	  peptide	  fragments	  in	  parallel	  to	  deduce	  specific	  epitopes.	  The	  peptide	  library	  is	  designed	  with	  overlapping	  peptide	  segments	  of	  the	  entire	  antigen,	  and	  T	  cell	  cultures	  are	  then	  added	  to	  the	  library.	  Binding	  can	  be	  assessed	  by	  flow	  cytometry	  and	  other	  cellular	  assays.	  Epitope	  discovery	  by	  this	  method	  has	  been	  especially	  useful	  for	   developing	   vaccines.	   Another	   method	   to	   identify	   T	   cell	   epitopes	   to	   a	   specific	  pathogen	   is	   to	   utilize	   online	   search	   engines,	   which	   consider	   HLA-­‐type	   and	   possible	  peptide	   presentation	   by	   the	  MHC	  molecule	   on	   the	   cell	   surface.	   The	   traditional	  whole	  genome	  library	  have	  the	  advantage	  of	  being	  HLA-­‐unbiased	  while	  predicative	  algorithms	  represent	  a	  more	  high	  throughput	  technology.	  In	  some	  cases,	  search	  engines	  may	  not	  be	  accurate	   in	   terms	   of	   identifying	   immunodominant	   epitopes,	   especially	   not	   in	   the	  unusual	   HLA-­‐types.	   Nevertheless,	   predicative	   algorithms	   do	   not	   require	   the	   same	  amount	  of	  material,	  which	  is	  most	  often	  a	  restriction	  in	  human	  patient	  samples.	  Hence	  in	  this	  thesis,	  we	  have	  only	  predicted	  epitopes	  through	  search	  engines	  and	  not	  used	  the	  traditional	  peptide	  libraries	  (Figure	  7).	  	  
            	  
Figure	   7.	   The	  NetCTL	   server	   integrates	   prediction	   of	   peptide-­‐MHC	   class	   I	   binding,	   proteasomal	   C	   terminal	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3 RESULTS	  AND	  DISCUSSION	  The	  studies	  in	  this	  thesis	  were	  performed	  on	  two	  cohorts.	  In	  one	  cohort,	  we	  utilized	  live	  attenuated	  YFV	  as	  a	  model	  for	  acute	  viral	  infection	  in	  humans	  by	  vaccinating	  21	  healthy	  individuals	   with	   YFV	   17D	   (Stamaril),	   and	   collecting	   peripheral	   blood	   mononuclear	  cells	  (PBMCs),	  sera	  and	  whole	  blood	  before	  (day	  0)	  and	  at	  days	  1,	  3,	  6,	  10,	  15,	  and	  90	  after	   vaccination	   (described	   in	  papers	   I	   and	   III).	   The	   other	   cohort	  was	   collected	   in	  collaboration	   with	   Kaunas	   hospital	   in	   Lithuania,	   where	   PBMCs,	   cerebrospinal	   fluid	  (CSF),	   sera,	   and	   whole	   blood	   were	   collected	   from	   20	   patients	   with	   confirmed	   TBE	  (IgM	   positive	   for	   TBEV	   in	   serum).	   Samples	   were	   obtained	   within	   3	   days	   after	  hospitalization	  (day	  0)	  and	  at	  days	  7,	  21,	  and	  90	  (described	  in	  papers	  II	  and	  IV).	  
3.1 HUMAN	  NK	  CELL	  RESPONSES	  TO	  FLAVIVIRUS	  INFECTIONS	  
3.1.1	  Infection	  with	  TBEV	  induces	  high	  levels	  of	  pro-­‐inflammatory	  cytokines	  	  Upon	   infection	  with	  a	  virus	  or	  another	  pathogen,	   immune	  cells	   release	   cytokines	  and	  the	   assessment	   of	   these	   cytokines	   in	   sera	   may	   provide	   for	   a	   good	   immunological	  overview	   of	   an	   ongoing	   infection.	   Thus,	   our	   first	   approach	   was	   to	   assess	   cytokine	  responses	  caused	  by	  YFV	  17D	  and	  TBEV	  infections.	  We	  focused	  on	  cytokines	  known	  to	  influence	   human	   NK	   cells	   (IL-­‐2,	   IL-­‐12,	   IL-­‐15,	   IL-­‐18,	   and	   IFN-­‐α),	   as	   well	   as	   on	   pro-­‐inflammatory	  cytokines	  and	  chemokines	  produced	  by	  NK	  cells	  (IFN-­‐γ,	  TNF	  and	  Mip-­‐1β).	  	  No	  significant	  increases	  of	  cytokines	  in	  sera	  were	  detected	  in	  YFV	  17D	  infection	  at	  any	  time	   point.	   However,	   we	   observed	   that	   NK	   cell-­‐activating	   cytokines	   significantly	  increased	  together	  with	  elevated	  levels	  of	  the	  NK	  cell	  effector	  cytokines	  IFN-­‐γ	  and	  TNF	  as	  well	  as	   the	  pro-­‐inflammatory	  cytokines,	   IL-­‐6	  and	  IL-­‐8,	   in	  TBEV-­‐infected	  patients	  at	  the	   time	   of	   hospitalization	   (paper	   II).	   These	   findings	   indicate	   that	  NK	   cells	   could	   be	  activated	  and	  involved	  in	  the	  immune	  responses,	  at	  least	  in	  patients	  with	  severe	  TBEV-­‐infection.	  Hence,	  we	  set	  out	  to	  study	  the	  NK	  cells	  and	  their	  activation	  in	  detail	  in	  human	  infections	  with	  TBEV	  and	  YFV.	  
3.1.2	  Flaviviruses	  activates	  NK	  cells	  	  One	   of	   many	   factors	   that	   may	   influence	   the	   development	   of	   symptomatic	   flavivirus	  infection	   is	   NK	   cell	   numbers	   and	   function.	   For	   example,	   it	   is	   observed	   that	   early	  activation	   and	   expansion	   of	   NK	   cells	   after	   infections	  with	  WNV	   and	   DENV,	   has	   been	  associated	   with	   viral	   control	   and	   prevention	   of	   disease	   in	   mice	   [130,	   131]	   and	   in	  humans	  [76,	  82,	  84].	  	  We	  were	  interested	  in	  studying	  the	  characteristics	  and	  kinetics	  of	  the	  NK	  cell	  activation	  caused	  by	  YFV	  17D	  and	  TBEV	   infections.	  To	   investigate	  NK	  cell	  activation	   induced	  by	  YFV	  17D	  and	  TBEV,	  we	  analyzed	  the	  expression	  of	  Ki67	  which	  is	  expressed	  in	  currently	  or	   recently	   dividing	   cells	   [132].	   Infection	   with	   YFV	   17D	   induced	   increased	   Ki67	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frequencies	   at	   day	   6	   and	   10	  within	   both	   CD56bright	   and	   CD56dim	   NK	   cell	   populations	  (paper	   I).	  TBEV	   infection	   induced	  significantly	   increased	  Ki67	   frequencies	   in	  CD56dim	  NK	  cells	  in	  the	  acute	  stage	  (day	  0)	  as	  compared	  to	  the	  convalescent	  phase	  (day	  90).	  In	  addition,	   activation	   of	   CD56dim	   cells	   preceded	   the	   activation	   of	   CD56bright	   cells	   that	  peaked	  at	  day	  7	  and	  21	  (paper	  II),	  which	  is	  distinct	  from	  that	  of	  infection	  with	  YFV	  17D,	  and	  may	  indicate	  abnormalities	  in	  the	  NK	  cell	  response	  pattern	  in	  patients	  infected	  with	  TBEV.	  	  To	  analyze	  how	  NK	  cell	  activation	  induced	  by	  YFV	  17D	  related	  to	  viral	  replication	  and	  IFN	  response,	  plasma	  viral	  load	  and	  levels	  of	  type	  I/III	  IFN	  were	  measured.	  Viral	  RNA	  was	  detected	  at	  day	  6	   in	  a	  majority	  of	   the	  donors,	  concurrent	  with	  an	   increase	   in	   the	  levels	  of	  type	  I/III	  IFN	  in	  plasma	  (paper	  I).	  Levels	  of	  type	  I/III	  IFN	  in	  plasma	  at	  day	  6	  correlated	  positively	  with	  NK	  cell	  activation,	  measured	  as	  CD69	  expression	  at	  day	  6	  and	  Ki67	   expression	   at	   day	   10	   (paper	   I).	   YFV	   17D	   co-­‐incubated	  with	   PBMC	   induced	   up-­‐regulation	  of	  CD69	  on	  NK	  cells,	  whereas	  purified	  NK	  cells	  did	  not.	  This	  up-­‐regulation	  of	  CD69	  on	  NK	  cells	  by	  YFV	  17D	  could	  be	  abrogated	  by	  the	  inhibition	  of	  the	  JAK	  signaling	  pathway	  with	  Pyridone	  6	  (paper	  I).	  These	  results	  indicated	  that	  the	  presence	  of	  other	  cell	  types	  is	  required	  for	  activation	  of	  NK	  cells	  during	  infection	  with	  YFV	  17D,	  and	  that	  activation	  was	  dependent	  on	  type	  I/III	   IFN.	  Despite	   the	  evidence	  of	  NK	  cell	  activation	  caused	  by	  TBEV	  infection,	  we	  did	  not	  detect	  significant	  alterations	  in	  the	  frequency	  of	  total	  NK	  cells	  among	  lymphocytes	  (paper	  II).	  One	  possible	  explanation	  may	  be	  that	  the	  activated	  NK	   cells	   are	   recruited	   to	   the	   CNS,	   or	   other	   tissues	  where	   the	   virus	  may	   be	  active.	  CD4	  T	  cell	  activation	  (paper	  IV)	  correlated	  with	  total	  NK	  cells	  at	  day	  0	  (paper	  II)	  in	  TBEV	  infection.	  No	  such	  correlation	  could	  be	  observed	  with	  CD8	  T	  cells	  and	  NK	  cells.	  This	   observation	   suggests	   that	   innate	   responses	   may	   rely	   upon	   early	   interactions	  between	  NK	  cells	  and	  CD4	  T	  cells	  in	  infection.	  	  	  	  To	  conclude,	  symptomatic	  TBEV-­‐infection	  cause	  a	  distinct	  activation	  pattern	  of	  NK	  cells,	  in	  which	  activation	  of	  CD56bright	  NK	  cells	  occurs	  after	  that	  of	  CD56dim	  NK	  cells,	  about	  one	  week	  following	  hospitalization	  (papers	  I	  and	  II).	  This	  further	  indicates	  that	  the	  kinetics	  of	  the	  NK	  cells	  also	  may	  be	  an	  important	  factor	  in	  the	  prevention	  of	  severe	  disease.	  
3.1.3	  NK	  cell	  differentiation	  is	  affected	  by	  TBEV	  and	  YFV	  17D	  infections	  	  CD56dim	  NK	   cell	   differentiation	   can	  be	  determined	  by	   the	  parallel	   analyses	   of	  NKG2A	  and	   CD57	   (Figure	   4).	   To	   determine	   whether	   NK	   cell	   differentiation	   was	   affected	   by	  infections	  with	  YFV	  17D	  and	  TBEV,	  we	  analyzed	  the	  expression	  of	  Ki67	  in	  combination	  with	  CD57	  and	  NKG2A	  in	  CD56dim	  NK	  cells	  as	  well	  as	  the	  expression	  of	  NKG2C.	  YFV	  17D	  infection	   induced	   increased	   expression	   of	   Ki67	   in	   CD57-­‐	   CD56dim	   NK	   cells	   at	   day	   10.	  Both	   CD57+	   and	   CD57-­‐	   subsets	   responded	   with	   similar	   kinetics	   (paper	   I).	   TBEV	  infection	   induced	   significantly	   higher	   frequencies	   of	   Ki67	   expression	   in	   the	   late	  differentiated	  CD57+	   subsets	  at	  day	  0	   compared	   to	  day	  90	   (paper	   II).	  Thus,	   infection	  with	  YFV	  17D	  caused	  activation	  of	  subsets	  that	  are	  more	  responsive	  to	  cytokines	  (CD57-­‐	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subsets)	  while	  infection	  with	  TBEV	  induced	  activation	  of	  subsets	  that	  respond	  better	  to	  target	  cells	  (CD57+	  subsets).	  This	  may	  indicate	  that	  activation	  of	  the	  less	  differentiated	  CD56dim	  NK	  cell	  subsets	  provides	  protective	  immunity	  during	  flavivirus	  infection.	  Expansion	   of	   CD56dim	   NK	   cells	   expressing	   the	   activating	   receptor	   NKG2C	   has	   been	  reported	  in	  CMV	  infection	  [72,	  133,	  134]	  as	  well	  as	  in	  other	  viral	  infections	  [68,	  69].	  As	  occurs	  in	  EBV	  and	  HSV-­‐2	  virus	  infections	  [74,	  75],	  we	  did	  not	  observe	  any	  expansion	  of	  NKG2C-­‐positive	   NK	   cells	   induced	   by	   YFV	   17D	   or	   TBEV	   infections	   (paper	   I	   and	   II),	  despite	  most	  of	  the	  donors	  being	  CMV	  seropositive.	  Nevertheless,	  it	  cannot	  be	  excluded	  that	  NKG2C+	  NK	  cells	  expand	  numerically	  at	  the	  site	  of	  local	  infection.	  For	  instance,	   in	  patients	   with	   celiac	   disease,	   intraepithelial	   T	   cells	   in	   the	   gut	   lumen,	   i.e.,	   the	   site	   of	  inflammation,	   become	   activated	   and	   express	   high	   levels	   of	   NKG2C,	   whereas	   the	  corresponding	  T	  cells	  in	  peripheral	  blood	  remained	  unaffected	  [134].	  	  
3.1.4	  CD56dim	  NK	  cell	  responses	  to	  target	  cells	  are	  impaired	  in	  TBEV	  infection	  Many	   viruses	   down-­‐regulate	  MHC	   class	   I	   on	   the	   surface	   of	   the	   infected	   cell	   to	   evade	  cytotoxic	  T	  cell	  responses,	  which	  may	  result	  in	  NK	  cell	  killing	  [135].	  Flavivirus	  infected	  target	   cells	   are	   reported	   to	   be	   protected	   from	   lysis	   by	   NK	   cells,	   and	   it	   has	   been	  suggested	  that	  this	  is	  a	  consequence	  of	  virus-­‐mediated	  MHC	  class	  I	  up-­‐regulation	  [136,	  137].	   At	   least	   two	   distinct	   mechanisms	   of	   immune	   evasion	   have	   been	   reported	   in	  flavivirus-­‐infections.	  First,	  flaviviruses	  increase	  MHC	  class	  I	  expression	  on	  infected	  cells	  [138],	  	  and	  even	  though	  increased	  MHC	  class	  I	  expression	  may	  result	  in	  enhanced	  T	  cell	  responses,	   the	   evolution	   of	   flaviviruses	   has	   probably	   been	   driven	   more	   by	   selective	  escape	  to	  innate	  immunity	  rather	  than	  adaptive	  T	  cell	  immunity	  [139].	  Second,	  the	  viral	  protein	   NS5	   can	   inhibit	   early	   phosphorylation	   events	   in	   the	   IFN	   signal-­‐pathway	   by	  acting	   as	   an	   IFN	   agonist	   [140],	   which	   has	   been	   observed	   in	   studies	   with	   TBEV	   and	  Langat	  virus.	  Similar	  strategies	  may	  be	  utilized	  by	  other	  flaviviruses	  such	  as	  WNV	  and	  JEV	   [141,	  142].	   Furthermore,	   it	   has	  been	   shown	   that	   JEV	   is	   able	   to	   inhibit	  CD8	  T-­‐cell	  responses	  by	  interfering	  with	  MHC	  class	  I	  antigen	  presentation	  [143].	  Antiviral	  responses	  by	  NK	  cells	  can,	  as	  mentioned	  above,	  be	  activated	  through	  cytokines	  like	   IL-­‐12	  and	   IL-­‐18	  or	  by	   the	  recognition	  of	  viral-­‐induced	  changes	  on	   infected	   target	  cells.	  We	  observed	  that	  infection	  with	  YFV	  17D	  induced	  increased	  expression	  of	  IFN-­‐γ	  and	  CD107a	  in	  CD56dim	  NK	  cells	  after	  stimulation	  with	  IL-­‐12	  alone,	  IL-­‐12	  and	  IL-­‐18	  in	  combination	   or	   in	   response	   to	   K562	   target	   cells	   (paper	   I).	   The	   functional	  responsiveness	   peaked	   at	   day	   6	   and	   returned	   to	   baseline	   levels	   at	   day	   15	   after	  vaccination.	  TBEV	  infection	  induced	  reduced	  degranulation	  and	  cytokine	  production	  of	  CD56dim	  NK	  cells	  in	  response	  to	  K562	  target	  cells	  at	  day	  0	  as	  compared	  to	  day	  90	  (paper	  
II).	  Surprisingly,	   the	  capacity	  to	  produce	  IFN-­‐γ	   in	  response	  to	  IL-­‐12/IL-­‐18	  stimulation	  was	  intact	  throughout	  infection	  with	  TBEV	  (paper	  II).	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We	   found	   that,	   in	   contrast	   to	   infection	   with	   YFV	   17D,	   TBEV	   infection	   induced	   a	  dampened	   NK	   cell	   response	   against	   target	   cells,	   but	   the	   responsiveness	   to	   cytokine	  activation	  remained.	  This	  further	  supports	  the	  hypothesis	  that	  viral	  escape	  is	  directed	  towards	   NK	   cells	   and	   moreover,	   that	   TBEV	   escape	   mechanisms	   in	   humans	   may	   be	  directed	   towards	   MHC	   class	   I	   target	   cell	   recognition	   since	   no	   dysfunctional	   changes	  could	  be	  observed	  in	  NK	  cells	  activated	  with	  cytokines.	  	  
3.1.5	  Effects	  of	  NK	  cell	  differentiation	  on	  the	  response	  to	  flavivirus	  infections	  Increased	   NK	   cell	   differentiation	   is	   associated	   with	   expression	   of	   multiple	   KIRs	   on	  single	  NK	  cells;	  therefore	  we	  asked	  whether	  the	  number	  of	  inhibitory	  KIRs	  affected	  the	  responsiveness	  of	  NK	  cells	  in	  these	  infections.	  We	  divided	  the	  NK	  cells	  into	  subgroups	  of	  cells	  expressing	  zero,	  one,	  two	  or	  three	  KIRs.	  NK	  cells	  that	  express	  zero	  or	  one	  KIR	  are	  considered	  as	  more	  responsive	  to	  cytokines	  and	  less	  responsive	  to	  target	  cells,	  whereas	  NK	  cells	   expressing	   two	  or	   three	  KIRs	  are	   considered	  as	   late-­‐differentiated	  and	  more	  responsive	  to	  target	  cells.	  We	  could	  not	  detect	  any	  differences	  in	  activation	  in	  NK	  cells	  that	  express	  zero,	  one,	  two	  or	  three	  KIRs	  over	  time	  after	  YFV	  17D	  infection	  (paper	  I).	  Conversely,	  TBEV	   infection	   induced	  significant	  activation	  of	   the	  NK	  cells	  expressing	  0	  KIR	   in	   the	   late	   differentiated	   CD57+NKG2A-­‐	   and	   CD57+NKG2A+	   subsets	   at	   day	   0	   as	  compared	  to	  day	  90	  (paper	  II).	  	  Explanations	  for	  the	  difference	  in	  the	  activation	  patterns	  in	  these	  subsets	  caused	  by	  YFV	  17D	  and	  TBEV	  infections	  may	  be	  either	  to	  due	  to	  the	  mild	  infection	  YFV	  17D	  causes,	  or	  that	  TBEV	  alters	  the	  immune	  response	  so	  that	  the	  NK	  cells	  become	  more	  responsive	  to	  cytokines	  instead	  of	  infected	  target	  cells.	  
3.2 HUMAN	  T	  CELL	  RESPONSES	  TO	  FLAVIVIRUS	  INFECTIONS	  
3.2.1	  T	  cells	  are	  activated	  in	  flavivirus	  infections	  There	   are	  many	   challenges	   in	   studying	   virus-­‐specific	   T	   cell	   activation	   in	   human	   viral	  infections.	   Epitopes	   are	   required	   to	   identify	   the	   nature	   of	   virus	   specific	   cells	   either	  through	  MHC	  class	  I	  tetramers,	  or	  through	  in	  vitro	  activation.	  However,	  T	  cell	  epitopes	  have	  not	  yet	  been	  identified	  for	  all	  viruses	  and	  further,	  one	  virus-­‐specific	  epitope	  does	  not	   represent	   the	   magnitude	   of	   all	   virus	   specific	   cells.	   To	   circumvent	   this	   problem,	  Miller	  et	  al.	  identified	  a	  set	  of	  general	  activation	  markers	  (CD38,	  HLA-­‐DR	  and	  Ki67),	  the	  measurement	   of	   which	   indicate	   the	   magnitude	   of	   the	   virus-­‐specific	   T	   cell	   response,	  independent	  of	  epitope-­‐	  or	  HLA-­‐specificity	  [27].	  	  Activation	  of	  immune	  cells	  is	  required	  to	  create	  protective	  immunity,	  and	  inhibition	  or	  alterations	  in	  the	  activation	  can	  affect	  acquired	  immunity	  against	  the	  pathogen.	  Thus,	  as	  a	   first	   approach,	  we	  wanted	   to	   study	  T	   cell	   kinetics,	  magnitude	   and	   activation	   of	   the	  virus-­‐specific	  T	  cells	   in	  YFV	  17D	  and	  TBEV	   infections.	  Based	  on	  the	  previous	  study	  of	  Miller	  et	  al.	  [27],	  we	  identified	  the	  virus-­‐specific	  cells	  using	  the	  activation	  marker	  CD38,	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in	   combination	  with	  Ki67.	   Activation	  was	  measured	   at	   day	   0,	   7,	   21	   and	   90	   in	   TBEV-­‐infected	   individuals,	   and	   before	   (BL)	   along	   with	   days	   10,	   15,	   and	   90	   post	   YFV	   17D	  administration	  to	  previously	  unvaccinated	  healthy	  individuals.	  	  Indeed,	  we	  detected	  a	  clear	  CD8	  T	  cell	  activation	  in	  both	  infections	  (papers	  III	  and	  IV).	  Infection	  with	  YFV	  17D	  induced	  CD8	  T	  cell	  activation	  that	  peaked	  around	  15	  days	  post	  vaccination	  and	  TBEV	  infection	  induced	  a	  later	  activation	  that	  peaked	  about	  one	  week	  after	   hospitalization,	   i.e.,	   the	   beginning	   of	   the	   second	   phase	   of	   disease.	   The	   activated	  (CD38+KI67+)	  cells	  expressed	  high	  levels	  of	  perforin,	  granzyme	  B,	  HLA-­‐DR,	  PD-­‐1,	  T-­‐bet	  and	  Eomes	  together	  with	  low	  levels	  of	  Bcl-­‐2,	  thereby	  defining	  these	  as	  cytotoxic	  effector	  cells	  (paper	  IV).	  We	  did	  not	  observe	  a	  difference	  comparing	  activated	  CD8	  T	  cells	  in	  the	  two	  infections	  (Figure	  8).	  This	  indicates	  that	  severity	  of	  disease	  may	  not	  always	  affect	  the	  magnitude	  of	  the	  antiviral	  CD8	  T	  cell	  response.	  Previous	  studies	  have	  suggested	  that	  nonspecific	  CD8	  T	  cells	  can	  be	  activated	  and	  perform	  cytotoxicity	  in	  the	  absence	  of	  TCR	  engagement	  [144,	  145],	  referred	  to	  as	  bystander	  activation.	  No	  CMV	  of	  EBV	  bystander	  activation	   is	   reported	   in	   YFV	   17D	   infection	   [27],	   and	   to	   address	   the	   possibility	   of	  recurring	   CMV	   in	   TBEV	   infection	  we	   studied	   Ki67	   expression	   in	   CMV-­‐specific	   CD8	   T	  cells.	   The	   Ki67	   expression	   was	   low	   in	   the	   CMV-­‐specific	   population	   and	   remained	   so	  throughout	  the	  course	  of	  infection	  in	  all	  tested	  donors,	  showing	  that	  no	  CMV-­‐bystander-­‐activation	  occurred	  (paper	  IV).	  This	  finding	  suggests	  that	  TCR	  engagement	  probably	  is	  the	  primary	  form	  of	  activation	  of	  the	  antiviral	  CD8	  T	  cells	  in	  response	  to	  TBEV	  and	  that	  bystander	  activation	  of	  CMV-­‐specific	  T	  cells	  is	  not	  a	  major	  feature	  in	  TBEV	  infection.	  	  













































Figure	  8.	  T	  cell	  activation	   induced	  by	  YFV	  17D	  
and	  TBEV	   infections.	   A)	   CD38+KI67+	  CD8	  T	   cells	  in	  YFV	  17D	   infection	  (day	  15)	  and	  TBEV	   infection	  (day	   7)	   were	   compared	   at	   the	   time	   of	   the	  maximum	   peak	   (left	   panel).	   CD38+KI67+	   CD4	   T	  cells	   induced	   by	   YFV	   17D	   infection	   (day	   10)	   or	  TBEV	  infection	  (day	  7)	  were	  compared	  at	  the	  time	  of	   the	   maximum	   peak	   (right	   panel).	   Statistical	  analysis	   was	   performed	   using	   Mann-­‐Whitney	   T	  test.	  *,	  p	  <	  0.05;	  **,	  p	  <	  0.01;	  ***,	  p	  <	  0.001	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a	  higher	  percentage	  of	  CD38+Ki67+	  CD4	  T	  cells	  as	  compared	  to	  TBEV	  infection	  (Figure	  8).	  The	  role	  of	  CD4	  T	  cells	  in	  TBEV	  infection	  is	  difficult	  to	  interpret,	  as	  the	  presence	  of	  IgM	   and	   IgG	   antibodies	   at	   the	   time	   of	   hospitalization	   suggests	   that	   the	   CD4	   T	   cell	  response	  is	  either	  biphasic	  or	  started	  before	  the	  onset	  of	  symptoms.	  Nevertheless,	  the	  activation	  of	  CD4	  T	  cells	  with	  the	  right	  magnitude	  and	  kinetics	  may	  be	  a	  requirement	  for	  viral	  clearance	  and	  protective	  immunity.	  	  	  
	  
	  	  	  	  	  	  	  	  Figure	  9.	  Collected	  data	  of	  the	  cell-­‐mediated	  immune	  responses	  against	  YFV	  17D	  and	  TBEV	  infections.	  	  
3.2.2	  T	  cell-­‐specific	  responses	  to	  flavivirus	  infections	  CD8	   T	   cells	   have	   a	   range	   of	   functions	   to	   control	   viral	   infections,	   and	   the	   functional	  properties	  of	  the	  specific	  T	  cells	  may	  play	  a	  major	  role	  in	  viral	  clearance.	  For	  instance,	  it	  has	  been	  observed	  that	  high	   levels	  of	  polyfunctionality	   in	   the	  CD8	  T	  cells	  response	  to	  HIV-­‐1	   infection	   is	   associated	  with	   slow	   disease	   progression	   [146].	   	   Adding	   a	   further	  layer	   of	   complexity,	   the	   magnitude	   of	   the	   CD8	   T	   cell	   response	   has	   been	   shown	   to	  correlate	  with	  selection	  of	  viral-­‐escape	  mutants	  during	  acute	  infection,	  rather	  than	  the	  level	  of	  polyfunctionality	  [147].	  DENV-­‐specific	  memory	  T	  cells	  are	  reported	  to	  influence	  the	   outcome	   of	   disease	   severity.	   T	   cells	   from	   patients	   with	   mild/sub	   clinical	   DENV-­‐	  infection	  preferably	  produced	  granzyme	  B	  upon	  antigen	  stimulation,	  while	   those	  who	  were	   hospitalized	  with	   the	  more	   severe	   form	  produced	   both	   TNF	   and	   IFN-­‐γ,	   or	   TNF	  alone	  [148].	  	  To	   assess	   the	   functional	   profile	   of	   YFV	   17D-­‐	   and	   TBEV-­‐	   specific	   CD8	   T	   cells,	   we	  constituted	   a	   pool	   of	   potential	   peptide	   epitopes	   predicted	   by	   the	   NetCTL	   algorithm	  [149].	  The	  predicted	  peptide-­‐pools	  were	  then	  used	  to	  activate	  virus-­‐specific	  CD8	  T	  cells	  
in	  vitro.	  YFV	  17D	  specific	  cells	  show	  a	  diverse	  response	  pattern	  that	  was	  dominated	  by	  mono-­‐,	  bi-­‐,	  and	  triple-­‐functional	  cells	  with	  respect	  to	  intracellular	  expression	  of	  IFN-­‐γ,	  IL-­‐2,	  MIP-­‐1β,	  TNF	  and	  surface	  expression	  of	  CD107a.	  The	  responses	  tended	  to	  become	  less	  polyfunctional	  over	  time,	  since	  monofunctional	  cells	  dominated	  the	  specific	  cells	  at	  day	  90	  (paper	  III	  and	  Figure	  10).	  The	  CD8	  T	  cell	  response	  to	  TBEV	  infection	  was	  almost	  undetectable	   in	  patients	   at	   the	   time	  of	   hospitalization.	   Similar	   to	  NK	   cells	   (paper	   II),	  significantly	   lower	   expression	   of	   CD107a,	   Mip-­‐1β	   and	   TNF	   at	   days	   0	   and	   7	   was	  observed,	   as	   compared	   to	   days	   21	   and	   90.	   Furthermore,	   TBEV	   specific	   CD8	   T	   cells	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primarily	  showed	  responses	  of	  a	  monofunctional	  nature	  that	  lasted	  over	  time	  (paper	  IV	  and	  Figure	  10).	  	  
	  	  Because	   the	   YFV	   17D	   provides	   a	   high	   level	   of	   protection,	   our	   observation	   that	   the	  response	   is	   dominated	   by	  mono-­‐,	   bi-­‐,	   and	   triple-­‐functional	   cells	   would	   be	   consistent	  with	   a	   model	   in	   which	   polyfunctionality	   with	   four	   of	   five	   functions	   is	   not	   a	   strict	  requirement	  for	  a	  protective	  CD8	  T	  cell	  response.	  TBEV-­‐specific	  CD8	  T	  cells	  showed	  low	  production	  of	  cytokines	  and	  was	  primarily	  mono-­‐functional	  and	  could	  possibly	  reflect	  functional	  inhibition	  and	  delay	  of	  the	  T	  cell	  caused	  by	  TBEV.	  






YFV day 15 Figure	   10.	   Functional	   properties	   of	   YFV	  
17D-­‐specific	  and	  TBEV-­‐specific	  CD8	  T	  cells.	  Pie	   charts	   indicate	   the	  mean	   composition	   of	  the	  total	  response	  in	  CD8	  T	  cells	  with	  regard	  to	  their	  capacity	  to	  express	  one,	  two,	  three	  or	  four	   functions	   at	   day	   15	   after	   vaccination	  with	  YFV	  17D	   (left	   panel)	   or	   at	   day	  21	   after	  hospitalization	   in	   patients	   infected	   with	  TBEV	  (right	  panel).	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After	   YFV	   17D	   administration,	   the	   HLA-­‐A2	   and	   HLA-­‐B7	   specific	   cells	   had	   detectable	  frequencies	  throughout	  the	  course	  of	  the	  response.	  During	  the	  effector	  response	  against	  YFV	   17D	   infection,	   the	  most	   prevalent	   phenotype	   of	   tetramer-­‐defined	   CD8	   T	   cells	   of	  both	  A2-­‐	  and	  B7	  specificities	  was	  TEM	  PD-­‐1+	  at	  day	  15,	  but	  at	  the	  memory	  stage	  at	  day	  90	  the	   specific	   cells	   had	   shifted	   to	   a	   TEMRA	   PD-­‐1-­‐	   phenotype	   (paper	   III).	   The	   HLA-­‐A2	  tetramers	  identified	  detectable	  frequencies	  of	  TBEV-­‐specific	  specific	  cells	  at	  day	  7	  and	  21	  after	  hospitalization,	  whereas	  tetramer-­‐positive	  cells	  were	  barely	  detectable	  at	  day	  0	  in	   TBEV	   infection	   (paper	   IV).	   The	  most	   dominant	   phenotype	   at	   day	   7	   of	   the	   TBEV-­‐specific	  CD8	  T	  cells	  was	  TEM	  CD57−PD-­‐1+.	  This	  phenotype	  contracted	  rapidly	  and	  was	  less	  prevalent	  at	  the	  convalescent	  phase	  (days	  21	  and	  90)	  (paper	  IV).	  	  In	   memory	   T	   cell	   subsets,	   the	   expression	   pattern	   of	   T-­‐bet	   and	   Eomes	   may	   differ	  depending	   on	   the	   antigen	   specificity.	   For	   instance,	   polyomavirus	   BK-­‐specific	   cells	  display	   a	   T-­‐bet	   intermediate	   and	   Eomes	   low	   phenotype.	   In	   the	   same	   donors,	   CMV-­‐specific	   cells	   are	   both	   T-­‐bet	   and	   Eomes	   high,	   whereas	   influenza-­‐specific	   cells	   are	   T-­‐bethigh	   and	  Eomeslow	   [150].	   Since	   the	  activated	   (Ki67+CD38+)	  CD8	  T	  cell	  population	   in	  TBE	   patients	   showed	   a	   distinct	   pattern	   of	   increased	   expression	   of	   T-­‐bet	   and	   Eomes	  (paper	  IV),	  we	  measured	  the	  expression	  of	  these	  transcription	  factors	  in	  TBEV-­‐specific	  CD8	  T	   cells	   in	   combination	  with	  Ki67.	  We	  observed	   a	   triple	   positive	   (Eomes+Ki67+T-­‐bet+)	   dominant	   phenotype	   among	   the	   TBEV-­‐specific	   CD8	   T	   cell	   population	   at	   day	   7,	  which	  retracted	  to	  become	  almost	  undetectable	  in	  the	  convalescent	  phase	  (paper	  IV).	  In	   the	   convalescent	   phase	   of	   disease,	   Eomes-­‐Ki67-­‐T-­‐bet+	   CD8	   T	   cells	   dominated	   the	  TBEV-­‐specific	  pool.	  This	  suggests	  that	  simultaneous	  up-­‐regulation	  of	  Eomes,	  Ki67,	  and	  T-­‐bet	  occurs	  in	  the	  effector	  phase	  of	  the	  T	  cell	  response	  against	  TBEV.	  In	  the	  memory	  stage,	  however,	  Ki67	  and	  Eomes	  are	  down	  regulated	  and	  T-­‐bet	  alone	  is	  dominant	  in	  the	  memory	  cells.	  This	  is	  consistent	  with	  the	  phenotype	  reported	  in	  influenza-­‐specific	  cells	  [150].	   Thus,	   long-­‐term	   human	  memory	   T	   cells	   specific	   for	   cleared	   infections	   such	   as	  influenza	  or	  TBEV	  may	  have	   a	   shared	  Eomeslow	  profile,	  which	   is	  distinct	   from	  T	   cells	  specific	  for	  persisting	  antigens	  such	  as	  CMV.	  	  Patients	  with	  severe	  TBEV	  infection	  might	  fail	  to	  clear	  the	  virus,	  and	  the	  responses	  we	  observed	  are	  most	  likely	  of	  dysfunctional	  nature.	  Despite	  the	  fact	  that	  no	  virus	  can	  be	  detected	   at	   any	   time	   in	   the	   TBE	   patients,	   specific	   CD8	   T	   cells	   arise	   one	   week	   after	  symptom	   debut.	   This	   suggests	   that	   the	   virus	   (or	   parts	   of	   it)	   can	   prime	   and	   induce	  specific	  CD8	  T	  cells.	  Activation	  of	  CD4	  T	  cells	  as	  well	  as	  NK	  cell	  activation,	  together	  with	  the	  seroconversion	  of	  IgG	  suggests	  that	  some	  adaptive	  activation	  occurred	  earlier	  in	  the	  TBE	  patients.	  This	  is	  further	  confirmed	  by	  the	  correlation	  of	  activated	  CD4	  T	  cells	  with	  NK	  cells	  (paper	  II).	  	  In	  DENV	  infection,	  DENV-­‐NS1	  is	  secreted	  and	  detected	  in	  blood	  and	  the	  levels	  of	  NS1	  in	  blood	   correlates	  with	  disease	  outcome.	  NS1	   is	   further	   shown	   to	   induce	   inflammation	  and	  endothelial	  permeability	  in	  mice	  regardless	  of	  viral	  presence	  and	  interestingly,	  this	  could	  be	  prevented	  by	  NS1	  vaccination	  [151].	  Hypothetically,	  because	  NS1	  is	  secreted	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by	  DENV,	  TBEV	  may	   in	  a	   similar	  way	  secrete	  viral	  proteins	   that	   in	   this	   case	  can	  pass	  through	  the	  blood	  brain	  barrier.	  Further	  and	  importantly,	  a	  vaccine	  directed	  to	  TBEV-­‐NS1	  (or	  other	  viral	  proteins)	  could	  possibly	  prevent	  or	  dampen	  the	  symptoms	  caused	  by	  TBEV.	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4 CONCLUDING	  REMARKS	  YFV	  17D	   is	   the	   ideal	   virus	   for	   the	  human	   immune	   system.	   It	   is	  optimized	   so	   that	   the	  immune	  system	  can	  clear	   the	  virus	  without	  symptoms	  (in	  most	  cases)	  and	  a	   life-­‐long	  protective	  memory	  is	  created.	  Herein,	  it	  is	  used	  as	  a	  model	  system	  to	  capture	  the	  early	  primary	   immune	   responses	   in	   a	   controlled	  model	   of	   acute	   viral	   infection	   in	   humans.	  Knowledge	  of	  the	  immune	  responses	  gained	  from	  YFV	  17D	  is	  then	  utilized	  to	  shed	  light	  on	   the	   immune	   responses	   in	   a	   natural	   infection	   with	   TBEV.	   Below	   are	   some	   major	  conclusions	  presented.	  	  
o Both	  YFV	  17D	  and	  TBEV	  infections	  induce	  activation	  of	  NK,	  CD4	  and	  CD8	  T	  cell	  subsets,	   and	   the	   activation	   caused	   by	   TBEV	   exerts	   a	   distinct	   immune	  activation-­‐pattern	  from	  that	  induced	  by	  YFV	  17D	  (papers	  I-­‐IV).	  	  
o The	   activation	   of	   NK	   cells	   induced	   by	   YFV	   17D	   infection	   relies	   on	   NK	   cell	  differentiation,	  and	  is	  likely	  primed	  by	  type	  I/III	  IFNs	  (paper	  I).	  
o Infection	   with	   TBEV	   induces	   a	   significant	   increase	   of	   cytokines	   in	   sera	   in	  parallel	  with	  an	  increase	  of	  	  less	  educated-­‐late	  differentiated	  CD56dim	  NK	  cells	  at	  the	  time	  of	  hospitalization	  (paper	  II).	  	  
o NK	  cell	  function	  in	  vivo	  is	  dampened	  by	  TBEV	  infection	  (paper	  II).	  	  
o Infection	  with	  YFV	  17D	  induces	  CD4	  T	  cell	  activation	  that	  precedes	  CD8	  T	  cell	  activation	   (paper	   III),	   but	   TBEV	   infection	   induce	   simultaneous	   activation	   of	  CD4	  and	  CD8	  T	  cell	  subsets	  (paper	  IV)	  
o YFV	  17D-­‐specific	  CD8	  T	  cells	  are	  mainly	  mono,	  bi	  and	  triple	  functional	  (paper	  
III),	   while	   TBEV-­‐specific	   CD8	   T	   cells	   primarily	   excert	   mono-­‐functional	  properties	  (paper	  IV).	  
o TBEV-­‐specific	  CD8	  T	   cells	  may	  also,	   as	  NK	  cells,	   be	   functionally	  dampened	  at	  the	  onset	  of	  symptoms,	  as	  the	  production	  of	  effector	  cytokines	  is	  significantly	  lower	   at	   the	   early	   timepoints	   after	   hospitalization,	   as	   compared	   to	   the	  convalescent	  phase	  of	  disease	  (paper	  IV).	  	  
o TBEV-­‐specific	  CD8	  T	  cells	  show	  a	  distinct	  transcriptional	  profile	  at	  the	  peak	  of	  activation	  that	  contracts	  and	  becomes	  almost	  undetectable	  in	  the	  convalescent	  phase	  (paper	  IV).	  	  Data	  presented	  herein	  offers	  an	  evaluated	  framework	  that	  adds	  to	  the	  understanding	  of	   the	   cell-­‐mediated	   immune	   regulation	   in	   flavivirus	   infections	   in	   humans.	   The	  application	  of	  this	  framework	  might	  yield	  a	  better	  understanding	  of	  the	  role	  that	  cell-­‐mediated	  immunity	  plays	  in	  other	  viral	  infections.	  Furthermore,	  it	  may	  be	  helpful	  for	  the	   insight	   in	   pathogenesis	   caused	   in	   viral	   infections	   as	   well	   as	   the	   design	   of	   new	  treatment	  regimens	  and	  the	  development	  for	  better	  vaccines	  to	  TBEV.	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